Licofelone is a dual COX/LOX inhibitor[1][2] that was studied in clinical trials as a treatment for osteoarthritis[3] and which was under development by Merckle GmbH with partners Alfa Wassermann and Lacer.
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.222.821 |
Chemical and physical data | |
Formula | C23H22ClNO2 |
Molar mass | 379.88 g·mol−1 |
| |
NY (what is this?) (verify) |
Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-lipoxygenase (5-LOX) may reduce the gastrointestinal toxicity associated with other nonsteroidal anti-inflammatory drugs (NSAID), which only inhibit cyclooxygenase (COX). Licofelone is the first drug to inhibit both.
Phase III trials for osteoarthritis were conducted in the early 2000s,[4][5] but results were mixed and the drug has never been submitted for regulatory approval.